Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Rafii on Durvalumab in Patients With Urothelial Bladder Cancer

Saeed Rafii, MD, PhD
Published: Tuesday, Jun 14, 2016



Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation and dose-expansion study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

The study examined the immunotherapy agent in a variety of solid tumors, Rafii says. In the urothelial bladder cancer cohort, the overall response rate was 25% in patients with liver metastases and 50% in patients with lymph node‒only disease. Response rates to chemotherapy for patients with this disease, he adds, have generally been low.

Additionally, responses are ongoing in 15 out of 16 patients enrolled in this study. The longest duration of response is ongoing at 11.3 months.


Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses a phase I/II dose-escalation and dose-expansion study examining the efficacy and safety of the PD-1 antibody durvalumab in patients with metastatic urothelial bladder cancer.

The study examined the immunotherapy agent in a variety of solid tumors, Rafii says. In the urothelial bladder cancer cohort, the overall response rate was 25% in patients with liver metastases and 50% in patients with lymph node‒only disease. Response rates to chemotherapy for patients with this disease, he adds, have generally been low.

Additionally, responses are ongoing in 15 out of 16 patients enrolled in this study. The longest duration of response is ongoing at 11.3 months.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x